Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 7:58 PM
Ignite Modification Date:
2025-12-24 @ 7:58 PM
NCT ID:
NCT01297504
Eligibility Criteria:
Inclusion Criteria:
* Children with a history of bronchopulmonary dysplasia, infants with a history of prematurity (less than or equal to 35 weeks gestational age), or children with hemodynamically significant congenital heart disease who received the first dose of palivizumab within the 2 weeks prior to the signature of the Informed Consent Form.
* Parent or legal guardian of child provides written Informed Consent
Exclusion Criteria:
* Children excluded from receiving palivizumab as per local guidelines
Healthy Volunteers:
False
Sex:
ALL
Maximum Age:
2 Years
Study:
NCT01297504
Study Brief:
Protocol Section:
NCT01297504